Ropinirole is a medication used for the treatment of idiopathic Parkinson's disease (PD), both as monotherapy in early disease and as an addition to levodopa (gold standard medication used for the treatment of PD) in advanced disease. It is also used for moderate-to-severe primary Restless Legs Syndrome (RLS). It selectively stimulates dopamine D2 and D3 receptors in the brain, specifically in the striatum, partially compensating for the loss of dopamine-producing neurons in Parkinson's disease.

Ropinirole is a non-ergot agonist that is commonly prescribed for the management of Parkinson’s disease and Restless Leg Syndrome. The positive aspect about ropinirole is that it does not increase the risk of cardiac valvular fibrosis or pulmonary/retroperitoneal fibrosis, which is commonly seen in other ergot-derived agents.

In Parkinson's disease, Ropinirole is used as initial monotherapy in early-stage disease, especially in younger patients who wish to delay the use of levodopa. It is also used as an adjunct in advanced disease to reduce the recurrence of symptoms when levodopa wears off (“off” time).

Unlike pramipexole (another medication used to treat PD & RLS), Ropinirole is metabolised in the liver by CYP1A2, hence smokers and those on antibiotics may require dosage alteration. However, Ropinirole avoids the motor fluctuations of long-term levodopa therapy and is often used as initial monotherapy in younger PD patients.

Idiopathic Parkinson's disease:

As monotherapy in early disease or as adjunctive therapy with levodopa in advanced disease.

Restless Legs Syndrome

Used to treat moderate-to-severe primary RLS.

Tremor-predominant Parkinson's disease

Particularly useful in younger patients to delay the use of levodopa.

• Effective monotherapy in early Parkinson's disease often delaying need for levodopa by months to years.

• Smooths motor fluctuations and reduces "off" time when added to levodopa in advanced PD.

• Lower risk of motor complications, such as dyskinesias (involuntary muscle movement), than levodopa monotherapy in early disease.

• Effective in primary RLS, with rapid symptom improvement.

• Lower risk of fibrotic complications.

• Available in once-daily extended-release form for convenience.

Common

• Nausea (especially while changing the dosage) and vomiting
• Sleepiness during the day
• Insomnia and weird dreams
• Dizziness and fatigue
• Orthostatic hypotension (drop in blood pressure upon standing)
• Headache
• Constipation and abdominal pain
• Dry mouth
• Peripheral oedema (swelling due to fluid buildup)

Uncommon

• Hallucinations (visual more common than auditory) and confusion

• Dyskinesias (uncontrolled muscle movement), when used with levodopa

• Weight gain or weight loss

• Dystonia (repetitive uncontrolled muscle movement), akathisia (inability to stay still)
• Increased blood pressure

Serious side effects requiring immediate attention

• Sudden-onset sleep attacks without warning, including while driving

• Impulse control disorders such as pathological gambling, hypersexuality, compulsive shopping, and binge eating

• Severe orthostatic hypotension with syncope (temporary loss of consciousness)

• Severe hallucinations or psychosis

• Dopamine agonist withdrawal syndrome on rapid discontinuation, which may cause anxiety, panic attacks, dysphoria and depression

• Augmentation in RLS (worsening of symptoms with treatment)

• Severe allergic reactions

Always follow the dosage prescribed by your doctor. Take Ropinirole orally exactly as prescribed. Generally, for Parkinson's disease, the immediate-release form is usually given in small quantities and is gradually titrated upwards weekly, typically in three divided doses. The extended-release form is taken once daily. For Restless Legs Syndrome, doses are much lower and are taken 1 to 3 hours before bedtime. Swallow tablets whole with water; do not crush or chew the extended-release tablets. May be taken with or without food, but taking it with food reduces nausea. Do not stop Ropinirole abruptly, as withdrawal can precipitate dopamine agonist withdrawal syndrome or a neuroleptic malignant-like syndrome in PD patients. The medicine should always be tapered under medical supervision.

Parkinson's disease develops when dopamine-producing nerve cells in a part of the brain called the substantia nigra gradually die. Dopamine is a chemical messenger that helps the brain control smooth, coordinated movement. As dopamine levels fall, the brain's movement-control circuits stop working properly, leading to the main symptoms of Parkinson's disease, which include slowness of movement, muscle stiffness, tremor at rest, and unsteady balance

[Ropinirole is a non-ergot dopamine agonist that directly stimulates dopamine receptors in the brain, bypassing the need for the body to produce its own dopamine. It selectively activates the D2 and D3 receptors, with minimal activity at D1, serotonin, adrenergic, or other receptors in the central nervous system.

By stimulating postsynaptic D2 and D3 receptors in the striatum (a deep brain nucleus), ropinirole partially restores dopamine signalling and improves motor function.

In Restless Legs Syndrome (RLS), the underlying problem involves disrupted dopamine signalling in the spinal and supraspinal pathways. Ropinirole activates dopamine receptors in these pathways, restoring normal sensory and motor signalling. This lowers the urge to move the legs and other unpleasant sensations of RLS.

Unlike levodopa, ropinirole:

• Does not require conversion to dopamine

• Has a longer half-life (approx. 6 hours)

• Stimulates dopamine receptors more steadily and continuously than levodopa, rather than in sharp pulses. This steadier stimulation reduces the risk of motor complications like dyskinesia and wearing-off when used alone in early Parkinson's disease.

Ropinirole is metabolised primarily by hepatic CYP1A2, which is induced by smoking and inhibited by ciprofloxacin and some other agents.

• Food (POSITIVE): Taking Ropinirole with food reduces nausea.

• Alcohol (SEVERE): Significantly increases sedation and sleep-attack risk.

• Caffeine (MILD): May counteract sedation but may worsen RLS in sensitive individuals.

• Tobacco / smoking (MODERATE): Smoking induces CYP1A2, lowering plasma Ropinirole by up to 30%. Inform your doctor of smoking status changes.

Dopamine antagonists (haloperidol, metoclopramide, prochlorperazine, risperidone)

SEVERE

Directly oppose ropinirole’s pharmacological effect. Hence, avoid taking them concurrently.

CYP1A2 inhibitors (Ciprofloxacin, fluvoxamine, mexiletine)

SEVERE

Significantly increase ropinirole levels (up to 100% increase with ciprofloxacin). Dose reduction required.

Smoking / tobacco (CYP1A2 inducer)

MODERATE

Reduces ropinirole levels by approx 30%. Adjust dose if smoking status changes.

CNS depressants (benzodiazepines, opioids, sedatives, alcohol)

SEVERE

Additional sedation and sleep-attack risk.

Antihypertensives

MODERATE

Additional risk of orthostatic hypotension.

Levodopa

CAUTION

Often co-prescribed, however, it may increase dyskinesias and hallucinations. Dose adjustment required.

Oestrogens (high-dose)

MODERATE

May reduce ropinirole clearance. Consider dose adjustment.

• Severe hepatic impairment (CONSULT YOUR DOCTOR): Low clearance. Dose adjustment may be needed.

• Cardiovascular disease, recent heart attack, or severe arrhythmias (USE WITH CAUTION): Risk of orthostatic hypotension.

• Psychotic disorders (USE WITH CAUTION): Increased risk of worsening.

• History of impulse control disorders, gambling, addiction (USE WITH CAUTION): Higher risk of recurrence.

• Sleep disorders or narcolepsy (USE WITH CAUTION): Increased risk of sleep attacks.

Overdosing may result in severe nausea, vomiting, agitation, hallucinations, hypotension, drowsiness, dyskinesias, and, in severe cases, coma or convulsions. Management includes stabilising the airway, breathing, and circulation. Activated charcoal may be considered for recent ingestion. Intravenous fluids could be administered for hypotension, and non-dopamine antagonist sedatives to treat agitation or psychosis. Cardiac and neurological monitoring is required. Seek immediate emergency care if overdosing is suspected.

Take a missed dose as soon as you remember on the same day. If it is close to the time of the next dose, skip the missed dose and continue your normal schedule. Do not double-dose as it can increase the risk of nausea, dizziness, and orthostatic hypotension. In Parkinson's disease, missing doses can cause symptom recurrence. In RLS, a missed evening dose may result in symptom return that night. If you miss several doses, contact your doctor before resuming.